The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Abstract
CONTEXT: The central role of platelet-rich thrombus in the pathogenesis of acute coronary syndromes (ACSs) is well-known. Glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor antagonists are potent inhibitors of platelet function that may be expected to affect favorably the natural history of ACSs. OBJECTIVE: To define the optimal role of Gp IIb/IIIa inhibitors in treatment strategies for ACSs. DATA SOURCES: A MEDLINE search was performed to identify all English-language articles regarding use of Gp IIb/IIIa inhibitors in ACSs published between 1966 and June 2000. In addition, relevant abstracts from the annual meetings of the American Heart Association, American College of Cardiology, and the European Society of Cardiology were reviewed. STUDY SELECTION: Only studies of 500 or more patients were included. Of 15 studies identified, 10 randomized, placebo-controlled, double-blind trials of Gp IIb/IIIa inhibitors in ACSs were selected for review. DATA EXTRACTION: Data quality was determined by publication in the peer-reviewed literature or presentation at an official cardiology society-sponsored meeting, as well as by verification with the primary author. DATA SYNTHESIS: Three members of this class of drugs are available for intravenous use. Abciximab, eptifibatide, and tirofiban hydrochloride, each have data demonstrating their value in improving the outcomes of patients presenting with ACSs. Current evidence supports use of these drugs in both conservative and invasive treatment strategies. Glycoprotein IIb/IIIa-blocking therapy is safe, and with proper precautions, bleeding risks can be minimized. Biological differences exist among these agents, but as of yet, no head-to-head comparisons have been made of their clinical efficacy. Unlike intravenous Gp IIb/IIIa inhibitors, available data regarding any role of oral Gp IIb/IIIa inhibitors are not favorable. CONCLUSION: Current data indicate that intravenous Gp IIb/IIIa inhibitor therapy merits a prominent role in the initial management of patients with ACSs. JAMA. 2000;284:1549-1558.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
(1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362401 · Cited by 1,883
(1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390704 · Cited by 1,432
Cohen, M., Demers, C., Gurfinkel, E. P., Turpie, A. G. G., Fromell, G. J., Goodman, S., Langer, A., Califf, R. M., Fox, K. A. A., Premmereur, J., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708143370702 · Cited by 1,424
Epistent Investigators, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)06113-3 · Cited by 1,346
Topol, E. J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)85010-1 · Cited by 1,095
Antman, E. M., McCabe, C. H., Gurfinkel, E. P., Turpie, A. G. G., Bernink, P. J. L. M., Salein, D., Bayes de Luna, A., Fox, K., Lablanche, J.-M., Radley, D., et al. (1999) · Circulation · doi:10.1161/01.cir.100.15.1593 · Cited by 1,052
Investigators, T. R. (1997) · Circulation · doi:10.1161/01.cir.96.5.1445 · Cited by 945
Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley, S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90007-8 · Cited by 838
Cited by
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.013 · Cited by 1,510
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 960
Diagnosis and Treatment of Acute Coronary Syndromes: A Review
Bhatt, D. L., Lopes, R. D., & Harrington, R. A. (2022) · JAMA · doi:10.1001/jama.2022.0358 · Cited by 787
Self-citationComposite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003) · JAMA · doi:10.1001/jama.289.19.2554 · Cited by 783
Metadata
- Authors
- Bhatt, D. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-09-27
- Volume
- 284
- Issue
- 12
- Pages
- 1549
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2077401512
- Cited by
- 269
- References
- 43
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. https://app.cochat.ai/papers/10.1001/jama.284.12.1549
- The paper
- Bhatt, D. L. (2000). Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA. https://doi.org/10.1001/jama.284.12.1549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.